Dr Charlotte Brierley
MA, BM BCh, MRCP
Wellcome Trust Clinical Research Fellow
Investigating the cellular and genetic landscape of myeloid neoplasms
I am a Wellcome Trust Clinical Research Fellow, working towards a DPhil in the haematopoietic stem cell biology group supervised by Prof Adam Mead and Dr Bethan Psaila. I am currently completing a visiting fellowship to Dr Elli Papaemmanuil’s group at Memorial Sloan Kettering Cancer Centre in New York.
I completed my undergraduate degree in medical sciences at the University of Cambridge and subsequent clinical medical training at Oxford. After qualifying I was awarded an NIHR Academic Foundation post in Edinburgh, after which I returned to Oxford as an Academic Clinical Fellow, allowing me to continue my research work alongside completing clinical training in haematology.
My research aims to understand how patients with acute myeloid leukaemia (AML) develop the disease, and why some respond to treatment better than others. My project uses single cell approaches to understand the genomic, proteomic and transcriptomic changes in blast-phase myeloproliferative neoplasms, a particularly aggressive type of AML. More widely, we hope that understanding the mechanisms of disease development, progression and response to therapy will lead to the identification of novel therapeutic targets to help patients with this disease.
A tale of two alleles: TP53 and transformation in MPNs.
Brierley C. and Psaila B., (2022), Blood, 139, 3567 - 3568
Molecular Characterisation of Participants in the Phazar Trial Reveals Prognostic Impact of Mutations in Advanced-Phase-MPN
Brierley CK. et al, (2020), BLOOD, 136
Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes.
Brierley CK. et al, (2020), Cancer, 126, 4735 - 4743
A NOVEL IN VITRO PLATFORM FOR THE PRIORITISATION AND VALIDATION OF INHIBITORS OF BONE MARROW FIBROSIS USING HUMAN BONE MARROW (BM) STROMAL CELLS
COLOMBO M. et al, (2020), HemaSphere, 4, 1 - 1168
Single-cell sequencing in hematology.
Brierley CK. and Mead AJ., (2020), Curr Opin Oncol, 32, 139 - 145